Abstract
Over the past 20 years, studies of transient receptor potential (TRP) channels have significantly extended our knowledge regarding the molecular basis of Ca2+ signals in cardiac myocytes. The functional significance of cardiac TRP channels is likely connected to the alteration of membrane potential or Ca2+ entry into a noncontractile compartment, where gene expression responsible for various cardiac diseases is induced. This review highlights some aspects of TRP channels with anticipated roles in cardiac disease. Evidence suggests that (a) increased activities of TRPC1, TRPC3, or TRPC6 are involved in the development of cardiac hypertrophy, where these TRPC channels act as unique sensors for a wide range of hypertrophic stimuli, and (b) mutations in TRPM4 are now recognized as causes of human cardiac conduction disorders. Ultimately, TRP channels may become novel pharmacological targets in the treatment of human cardiac disease.
Keywords: Cardiac arrhythmia, cardiac hypertrophy, Orai1, Stim1, TRPC1, TRPC3, TRPC6, TRPM4
Current Topics in Medicinal Chemistry
Title:Possible Involvement of TRP Channels in Cardiac Hypertrophy and Arrhythmia
Volume: 13 Issue: 3
Author(s): Hiroyuki Watanabe, Kenji Iino, Takayoshi Ohba and Hiroshi Ito
Affiliation:
Keywords: Cardiac arrhythmia, cardiac hypertrophy, Orai1, Stim1, TRPC1, TRPC3, TRPC6, TRPM4
Abstract: Over the past 20 years, studies of transient receptor potential (TRP) channels have significantly extended our knowledge regarding the molecular basis of Ca2+ signals in cardiac myocytes. The functional significance of cardiac TRP channels is likely connected to the alteration of membrane potential or Ca2+ entry into a noncontractile compartment, where gene expression responsible for various cardiac diseases is induced. This review highlights some aspects of TRP channels with anticipated roles in cardiac disease. Evidence suggests that (a) increased activities of TRPC1, TRPC3, or TRPC6 are involved in the development of cardiac hypertrophy, where these TRPC channels act as unique sensors for a wide range of hypertrophic stimuli, and (b) mutations in TRPM4 are now recognized as causes of human cardiac conduction disorders. Ultimately, TRP channels may become novel pharmacological targets in the treatment of human cardiac disease.
Export Options
About this article
Cite this article as:
Watanabe Hiroyuki, Iino Kenji, Ohba Takayoshi and Ito Hiroshi, Possible Involvement of TRP Channels in Cardiac Hypertrophy and Arrhythmia, Current Topics in Medicinal Chemistry 2013; 13 (3) . https://dx.doi.org/10.2174/1568026611313030006
DOI https://dx.doi.org/10.2174/1568026611313030006 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: The Endothelin System: Vascular Targets for Therapy in Disease (Guest Editor: Michael R. Dashwood)]
Current Vascular Pharmacology Melanocortins As Innovative Drugs for Ischemic Diseases and Neurodegenerative Disorders: Established Data and Perspectives
Current Medicinal Chemistry Mechanosensitive Ion Channels as Drug Targets
Current Drug Targets - CNS & Neurological Disorders ACE and ACE2 in Inflammation: A Tale of Two Enzymes
Inflammation & Allergy - Drug Targets (Discontinued) Rate and Predictors of Permanent Pacemaker Implantation After Transcatheter Aortic Valve Implantation: Current Status
Current Cardiology Reviews Purines and Pyrimidines: Metabolism, Function and Potential as Therapeutic Options in Neurodegenerative Diseases
Current Protein & Peptide Science Orai1 and Transient Receptor Potential Channels as Novel Molecular Targets to Impair Tumor Neovascularization in Renal Cell Carcinoma and other Malignancies
Anti-Cancer Agents in Medicinal Chemistry Exercise as Treatment for Neuropathy in the Setting of Diabetes and Prediabetic Metabolic Syndrome: A Review of Animal Models and Human Trials
Current Diabetes Reviews Potential Mechanisms of Failure in the Sudden Infant Death Syndrome
Current Pediatric Reviews Molecular Imaging to Monitor Repair of Myocardial Infarction Using Genetically Engineered Bone Marrow-Derived Mesenchymal Stem Cells
Current Gene Therapy Current Biological Therapies for Inflammatory Bowel Disease
Current Pharmaceutical Design Pharmacotherapy of Schizophrenia: The Past, Present and Future
Current Drug Therapy Biochemical Markers of Cardiovascular Damage from Tobacco Smoke
Current Pharmaceutical Design Patent Selections
Recent Patents on Cardiovascular Drug Discovery Renin--Angiotensin System Gene Polymorphism and Regression of Left Ventricular Hypertrophy in Hypertension
Current Pharmacogenomics Non-Pharmacologic Strategies in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19
Cardiovascular & Hematological Disorders-Drug Targets The Immunologic Barriers to Replacing Damaged Organs
Current Immunology Reviews (Discontinued) Colloid Update
Current Pharmaceutical Design Reducing the Risk of Major Elective Non-cardiac Surgery: Is there a Role for Levosimendan in the Preoperative Optimization of Cardiac Function?
Current Drug Targets